Global Cardiology Academy

Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
On the Frontlines of ATTR-CM
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
- Ryan Quigley
- Quan Bui, MD
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Heart Matters
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
- Quan Bui, MD
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
AudioAbstracts
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
- Hallie Blevins, PhD
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Heart Matters
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
AudioAbstracts
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
- Hallie Blevins, PhD
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Heart Matters
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Heart Matters
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
Heart Matters
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
- Laurence Sperling, MD
- Eugenia Gianos, MD

Programs

No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
AudioAbstracts
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
- Marlene Mimi Maeusli, PhD.
Advancing Care for Women With Aortic Stenosis: 2-Year Outcomes for Women in the 5-Year SMART Trial
Advancing Care for Women With Aortic Stenosis: 2-Year Outcomes for Women in the 5-Year SMART Trial
Cardiology
Advancing Care for Women With Aortic Stenosis: 2-Year Outcomes for Women in the 5-Year SMART Trial
- Roxana Mehran, MD, FSCAI
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Cardiology
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
- Pam R. Taub, MD, FACC, FASPC
Clinical Perspective on New Therapies in Resistant Hypertension
Clinical Perspective on New Therapies in Resistant Hypertension
Cardiology
Clinical Perspective on New Therapies in Resistant Hypertension
- Clyde W. Yancy, MD
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart Matters
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
- Jun-ichi Abe
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart Matters
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
CME/CE
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
0.25 credits
- Scott Solomon, MD
0.25 credits

Clinical Practice

Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Heart Matters
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
- Ahmad Masri, MD, MS
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Heart Matters
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
- Kevin Alexander
The Fifth Pillar? Closing the Gap in HFrEF
The Fifth Pillar? Closing the Gap in HFrEF
CME/CE
The Fifth Pillar? Closing the Gap in HFrEF
0.50 credits
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Javed Butler, MD
- Stephen J. Greene, MD, FACC, FHFSA
0.50 credits
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
On the Frontlines of ATTR-CM
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
- Shelina Ramnarine, PhD
- Quan Bui, MD
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Cardiology
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
- Christopher Wong
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Cardiology
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
- Clyde W. Yancy, MD
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Cardiology
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
- Jung-Sun Kim, MD, PhD
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Cardiology
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
- Atul Verma, MD

CME

Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
CME/CE
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
0.25 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Prof. Dr. Francesc Xavier Cos Claramunt
0.25 credits
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
CME/CE Broadcast Replay
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
0.50 credits
- Iacopo Olivotto, MD
- Ahmad Masri, MD, MS
- Pablo Garcia-Pavia, MD, PhD
- Fabian Knebel, MD, PhD
- Caroline Coats, MD
0.50 credits
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast Replay
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
0.50 credits
- Prof. Ulrich Laufs
- Pam R. Taub, MD, FACC, FASPC
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Christie Ballantyne, MD
0.50 credits
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Cardiology
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
- Daniel Judge, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Cardiology
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
- Kevin Alexander, MD
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Cardiology
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
- Ahmad Masri, MD, MS
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits
MinuteCE®
From Risk to Results: Cases in ASCVD Prevention and Treatment
1.00 credit 10 episodes
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 credit 10 episodes